Bristol Myers Squibb (BMY) is experiencing a rebound after a significant 11% drop, yet it remains below its March peak. With a forward price-to-earnings ratio of 9.4, the stock appears appealing for value investors. However, potential buyers should be cautious due to substantial risks, particularly a looming patent cliff that could impact revenue from key products like Revlimid, Eliquis, and Opdivo, which are set to lose exclusivity by 2028.
The company has made several acquisitions to enhance growth prospects, but these come with integration and clinical risks. While Bristol Myers Squibb’s growth portfolio is gaining traction, it still heavily relies on legacy products, which accounted for nearly half of total revenue. With only a 1% increase in revenue on a constant-currency basis, there’s concern that new drugs may not compensate for losses from older ones.
For investors, the decision to buy Bristol Myers Squibb on the dip hinges on individual risk tolerance. Risk-averse investors may want to explore other options, while those with a long-term perspective and an appetite for risk could find value in its 4.2% dividend yield.
Source: fool.com